Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma | bioRxiv
Therapeutic options for targeting myeloma epitopes, in this case, BCMA;... | Download Scientific Diagram
Effective anti-BCMA retreatment in multiple myeloma - ScienceDirect
Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? | Leukemia
CAR T-cell therapy for multiple myeloma: state of the art and prospects - The Lancet Haematology
CAR T-cell therapy in multiple myeloma: more room for improvement | Blood Cancer Journal
Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia - ScienceDirect
A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches | Leukemia
Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages: Molecular Therapy - Methods & Clinical Development
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma | Journal of Hematology & Oncology | Full Text
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma | Nature Communications
BCMA-targeted immunotherapy for multiple myeloma | Journal of Hematology & Oncology | Full Text
Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma | Journal of Clinical Oncology
Frontiers | Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma | Haematologica
Different constructs of CARs targeting BCMA. BCMA is an antigen that... | Download Scientific Diagram
CIMB | Free Full-Text | sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice - Parikh - CA: A Cancer Journal for Clinicians - Wiley Online Library
B-Cell Maturation Antigen | Research | BMS Science | HCP Site
Bristol Myers Squibb - U.S. Food and Drug Administration Approves Bristol Myers Squibb's and bluebird bio's Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma
Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma | PNAS
Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies - ScienceDirect
VisualAbstract: Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma | 2 Minute Medicine
